MAPK3 and cancer: Suppressing HER3 expression in cancer cells which harbor endogenous HER3 mutations reduced MAPK (ERK1/2) signaling but not AKT, indicating that HER3 mutants may preferentially activate MAPK signaling over AKT-dependent mechanisms.